Whitney Valins, BS; Clinical Research Fellow, University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida; Sadegh Amini, MD; bSenior Clinical Research Fellow, University of Miami Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida; Brian Berman, MD, PhD, Professor of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida Read the rest of this article »

Susan Weinkle, MD; Private Practice, Bradenton, Florida; Mohs Surgery/Skin Cancer, University of South Florida, Tampa, Florida; Mary Lupo, MD, Private Practice, New Orleans, Louisiana Read the rest of this article »

Katherine Fening, MD; Mark Bechtel, MD; Sara Peters, MD; Matthew Zirwas, MD; and Kamruz Darabi, MD

The Ohio State University College of Medicine and Public Health, Division of Dermatology, and
Department of Pathology, Section of Dermatopathology, Columbus, Ohio

Disclosure: Dr. Bechtel is a speaker for and has received honoraria from Steifel. Dr. Zirwas is a speaker for and has received honoraria from Astellas. He is also a speaker and consultant for Coria Labs and receives honoraria from Coria Labs. Drs. Bechtel, Zirwas, Peters, and Darabi are employed by OSU Medical Center. Dr. Fening reports no relevant conflicts of interest. Read the rest of this article »

Joshua A. Zeichner, MD
Mount Sinai Medical Center, New York, New York

Disclosure: Dr. Zeichner is a consultant for Promius Pharma.

Abstract
Psoriasis in some body parts can be challenging to treat. Psoriasis in the scalp, palms and soles, and intertriginous areas differ from disease on other body parts, and treatment regimens must be tailored to these areas. The presence of hair, along with the frequent, thick scale of psoriasis makes the scalp a challenge to treat. Skin in the body’s intertriginous areas is often thin, limiting treatment options for inverse psoriasis. Finally, palmoplantar psoriasis is often resistant to topical therapies because of the thickness of the skin. Moreover, cosmetic acceptibilty of a topical medicine is important when treating these areas. Coal tar has been used to treat psoriasis for hundreds of years. In a novel foam vehicle, coal tar 2% is versatile and may be used to treat psoriasis even in challenging areas of the body, such as the scalp, intertriginous areas, and palms and soles.  (J Clin Aesthet Dermatol. 2010;3(9):37–40.) Read the rest of this article »

Marc A. Bjurlin, DO; Jens Carlsen, DO; Division of Urology, Department of Surgery, Cook County Health and Hospitals System, Cook County Hospital, Chicago, Illinois; Mark Grevious, MD, Division of Plastic Surgery, Department of Surgery, Cook County Health and Hospitals System, Cook County Hospital; Michael D. Jordan, DO, Division of Urology, Department of Surgery, Cook County Health and Hospitals System, Cook County Hospital, Chicago, Illinois; Aisha Taylor, MD, Northwestern University, Department of Urology, Chicago, Illinois; Naveen Divakaruni, DO, Division of Urology, Department of Surgery, Cook County Health and Hospitals System, Cook County Hospital, Chicago, Illinois; Courtney M. P. Hollowell, MD, Division of Urology, Department of Surgery, Cook County Health and Hospitals System, Cook County Hospital, Chicago, Illinois Read the rest of this article »

Dominique Fausto de Souza, MD, Sector of Dermatology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Lilian Micaelo, MD, Sector of Dermatology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Tullia Cuzzi, MD, PhD, Sector of Pathology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Marcia Ramos-e-Silva, MD, PhD, Sector of Dermatology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Abstract
Plantar fibromatosis, or Ledderhose disease, is a rare hyperproliferative disorder of the plantar aponeurosis. It may occur at any age with the greatest prevalence at middle age and beyond. This disorder is more common in men than woman and it is sometimes associated with other forms of fibromatosis. A 28-year-old Brazilian woman with a six-year history of painless bilateral plantar nodules is described in this article.  (J Clin Aesthet Dermatol. 2010;3(9):45–47.) Read the rest of this article »

Valerie D. Callender, MD is from Callender Skin and Laser Center, Mitchellville, Maryland. Norman Preston, PhD; Cris Osborn, PhD; Lori Johnson, PhD; and Ronald W. Gottschalk, MD are from Galderma Laboratories, LP, Fort Worth, Texas

Disclosure: Dr. Callender is a clinical researcher and consultant for Galderma. Drs. Preston, Osborn, Johnson, and Gottschalk are employed by Galderma. Read the rest of this article »

Jason J. Emer, MD; Amylynne Frankel, MD; Joshua A. Zeichner, MD
Mount Sinai School of Medicine, Department of Dermatology, New York, New York

Disclosure: Drs. Emer and Frankel report no relevant conflicts of interest. Dr. Zeichner is an investigator for Centocor.

Abstract
Psoriasis is a chronic, systemic, inflammatory skin condition that manifests predominantly as well-demarcated, erythematous, scaly plaques on the elbows, knees, and scalp. While mild cases (minimal body surface) often respond to various topical treatments and light therapy, patients with extensive disease (larger body surface and possibly joint involvement) may require systemic medications for remission. The development of biological agents provides dermatologists valuable ways to help treat psoriatic disease quite efficiently, but literature regarding the monitoring of patients on biological treatments is sparse. Clinical practice varies widely since there is modest strong evidence to recommend or refute most tests currently recommended by the United States Food and Drug Administration. The purpose of this article is to present a practical approach to monitoring patients on biological therapy based on the most up-to-date literature.  (J Clin Aesthetic Dermatol. 2010;3(8):20–26.) Read the rest of this article »

Richard N. Sherman, MD
Skin Institute of New Orleans, New Orleans, Louisiana; Clinical Associate Professor,
Department of Dermatology, Tulane University, New Orleans, Louisiana

Disclosure: Dr. Sherman is a speaker, master trainer, and advisory board member for Sanofi-Aventis U.S. LLC. Editorial support for this article was provided by the editorial staff at Embryon. This article was funded by Dermik Laboratories, a business of Sanofi-Aventis U.S. The author gratefully acknowledges Marci Mikesell, PhD, who assisted in the preparation of this article based on author-provided comments. The author was fully responsible for the content, editorial decisions, and opinions expressed in the current article. The author received no honoraria or other form of financial support related to the development of this manuscript. Read the rest of this article »

Steven M. Dean, DO, FACP, RPVI; Matthew Zirwas, MD
The Ohio State University, Columbus, Ohio

Disclosure: Drs. Dean and Zirwas report no relevant conflicts of interest.

Abstract
Pyoderma gangrenosum is a painful, noninfectious, ulcerative, cutaneous disorder that most commonly affects the lower extremities. The diagnosis is made by recognizing the characteristic clinical manifestations in the setting of a causative systemic disease and excluding other causes of similar-appearing ulcerations. Pyoderma gangrenosum often evolves in the setting of systemic illnesses, such as inflammatory bowel disease, rheumatological disorders, and hematological conditions. However, several medications have rarely been linked to pyoderma gangrenosum. The authors report the second case of sunitinib-associated pyoderma gangrenosum in a 61-year-old patient with recurrent renal cell carcinoma.  (J Clin Aesthetic Dermatol. 2010;3(8):34–35.) Read the rest of this article »